Main Library
Key Takeaways
- Persistent underperformance of prior oncology VBC models reflects failure to measurably improve outcomes while lowering total cost, sustaining skepticism despite ongoing urgency to redesign care delivery.
- Population-based infrastructure leveraging claims, HIE feeds, onboarding assessments, ePROs, and predictive modeling enables risk stratification and earlier intervention to prevent avoidable ED use and admissions.
Value-based care (VBC) has not delivered the benefits its supporters envisioned, especially in oncology. Multiple models, from commercial payers to the Oncology Care Model from the Center for Medicare and Medicaid Innovation1 to, most recently, the Enhancing Oncology Model,2 have not produced expected benefits. The reasons for failure are vast and numerous, but time and again, the oncology community has been unable to show improved outcomes for patients with cancer while simultaneously reducing cost. Many ask, how does Thyme Care, as a VBC company, continue to grow and succeed in this world? Why do we continue to forge ahead?